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Introduction
In 1985 there were approximately 30 million people with 
diabetes worldwide. This figure had risen to 285 million 
by 2010, and is projected to rise to 438 million by 2030. 
This exponential increase is associated to a large extent 
with a growing obesity epidemic. Type 2 diabetes mellitus 
is associated with an approximately twofold increased 
mortality, largely due to macrovascular diseases such 
as coronary artery disease and stroke. Patients with 
type 2 diabetes mellitus are also prone to microvascular 
complications such as retinopathy, which is the main cause 
of blindness in the developed world, and neuropathy, 
which is also responsible for much suffering and disability. 
Macrovascular disease and neuropathy are important 
factors causing lower extremity amputations. It is estimated 
that the cost of diabetes complications accounts for five to 
10% of the total healthcare spending in the world.1
Principles of management in non-
pregnant adults
Diabetes is a chronic illness which requires not only continuing 
medical care, but also continuing patient self-management, 
education and support.2 Diabetes management extends 
beyond glycaemic control: the Steno-2 study showed that 
intensive multifactorial intervention, which included strict 
attention to the management of cardiovascular risk factors, 
was more cost-effective than conventional treatment.3 
An organised multidisciplinary team is essential for the 
implementation of comprehensive care for type 2 diabetes 
mellitus.
Initial evaluation of a patient with type 2 diabetes mellitus 
should include a comprehensive clinical assessment. 
Medical history should include age and initial presentation, 
eating patterns, physical activity, and associated conditions 
and therapies. Physical examination should include height, 
weight, body mass index (BMI), waist circumference 
and blood pressure (BP) measurement, and fundoscopic 
examination, skin and comprehensive foot examination.2
According to the Society for Endocrinology, Metabolism and 
Diabetes of South Africa (SEMDSA), laboratory examination 
should include HbA1c, a lipid profile, urine for microalbumin 
and serum creatinine at the initial consultation.4
Lifestyle interventions
Medical nutritional therapy should be individualised and 
should be provided by a registered dietitian. Weight loss 
by reduction in total calorie intake is recommended for 
all overweight patients; even a modest reduction of 5% 
of body weight has been associated with significant 
health benefits. Eliminating simple sugars and reducing 
the amount of rapidly absorbed carbohydrates with 
substitution of more slowly assimilated fibre-rich starches 
is strongly advised. A reduction in saturated fat intake, with 
substitution of polyunsaturated with monounsaturated fats, 
is recommended. Regular physical activity, both aerobic 
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Case scenario
A 55-year-old Asian man presents with a history of intense thirst, polyuria, blurring of vision and weight loss over a period 
of several weeks. He is obese with a waist circumference of 110  cm and a body mass index (BMI) of 32 kg/m2. His 
blood pressure is 170/110 mmHg. Laboratory investigations indicate the following: random blood glucose 13.6 mmol/l, 
haemoglobin A1c (HbA1c) 9.5%, total serum cholesterol 6.8 mmol/l, low-density lipoprotein (LDL) cholesterol 3.5 mmol/l, 
high-density lipoprotein (HDL) cholesterol 0.7 mmol/l, triglycerides 3.2 mmol/l, and serum creatinine normal. His urine shows 
glycosuria and microalbuminuria.
What would be your approach to this patient’s management?
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and strength training, should be part of comprehensive 
care. Current recommendations are at least 150 minutes 
per week of moderate-intensity exercise.5 Patients must be 
evaluated, not only for contraindications and limitations to 
physical activity, but also for weight loss targets. Exercise 
prescription should be developed to improve functional 
capacity, to decrease risk of falls and fractures, and to effect 
weight loss. Regular exercise helps to maintain weight 
loss, and improves insulin sensitivity, the lipid profile, and 
glycaemic and BP control. Caution should be exercised 
in those with coronary artery disease. Smoking should be 
prohibited in all patients.
Glycaemic control
There is incontrovertible evidence that good glycaemic 
control is of benefit, especially with respect to prevention 
or reduction of microvascular complications.6 The aim of 
glycaemic treatment is to achieve the recommended targets 
with as few adverse events as possible. Monitoring of 
glucose may be achieved by self-monitoring by the patient 
or long-term monitoring of glycated haemoglobin by the 
healthcare provider. HbA1c is formed by non-enzymatic 
attachment of glucose to the N-terminal valine of the β 
chain of haemoglobin. It represents glycaemic control 
over the preceding eight to 12 weeks, as the life span of 
the erythrocyte is approximately 120 days.7 It has many 
advantages but it is important to be aware of some of the 
pitfalls with this measurement, such as conditions that may 
alter the erythrocyte lifespan or interfere with measurement 
such as haemoglobinopathies, as well as cost and lack of 
routine availability and standardisation.
Self-monitoring of blood glucose (SMBG) should be carried 
out three or more times daily by patients using multiple 
insulin injections. For patients on less frequent injections 
SMBG should still be encouraged, and for patients on non-
insulin therapies, SMBG is not essential but may be a useful 
guide to success of therapy.2 
The HbA1c target has been a subject of much controversy 
lately. SEMDSA recommends HbA1c of less than 7%, but 
emphasises that goals should be individualised based on 
duration of diabetes, co-morbid conditions, pregnancy 
status, hypoglycaemia unawareness, age and individual 
patient considerations.4 The American Diabetes Association 
(ADA) is in agreement with SEMDSA, also recommending an 
HbA1c target of less than 7%.2 HbA1c should be measured 
twice yearly in those patients who are meeting their goals, 
and quarterly in those whose therapy has changed or who 
are not meeting their glycaemic goals. The major benefit 
of the HbA1c measurement is the strong predictive value 
for microvascular complications.8 The benefits of intensive 
glycaemic control on microvascular and neuropathic 
complications are well established and should not prompt 
clinicians to abandon the target of an HbA1c under 7%.9,10 
However, less stringent goals may be appropriate for some 
selected patients, as “one size does not fit all.” A recent 
study has prompted a reconsideration of the target HbA1c 
level in patients with type 2 diabetes mellitus: it showed 
a general U-shaped association between the HbA1c and 
outcome, with the lowest hazard ratio at an HbA1c of about 
7.5%.11
Pharmacological treatment of diabetes mellitus should 
complement lifestyle modification. It is important to 
emphasise to the patient that the natural history of diabetes 
will invariably lead to escalation of the initial therapy with 
time and that insulin therapy is almost invariably required, 




Metformin is the initial therapy of choice and should be 
commenced at the time of diagnosis in all patients, unless 
contraindicated. Metformin is a biguanide and its mode 
of action includes reduction of hepatic insulin resistance, 
gluconeogenesis and glucose release. The expected 
decrease in HbA1c is about 1 to 2%. It is recommended 
that metformin be continued when other therapies 
(including insulin) are added.13 The major adverse effects 
are gastrointestinal in nature and, rarely, include lactic 
acidosis (in patients with impaired renal, hepatic and cardiac 
dysfunction, as well as alcohol abuse). 
Recently, a number of publications have attested to the 
fact that metformin is associated with lower cancer risk in 
patients with type 2 diabetes mellitus.14-17 New extended-
release tablets should be considered when gastrointestinal 
side-effects pose a problem and prevent continuation of 
metformin. It is worth noting that metformin use may be 
associated with vitamin B12 deficiency over time.
5
Sulphonylureas
Sulphonylureas may be used as first-line therapy when 
HbA1c is above target and the patient is of normal weight 
or is intolerant to metformin. They can also be added as 
second-line agents to metformin.4 Sulphonylureas belong 
to a group of drugs known as insulin secretagogues, and 
lower glycaemia by enhancing insulin secretion. They 
lower HbA1c by approximately 1.5% and cause weight 
gain of around 2 kg.18 The other common adverse effect is 
hypoglycaemia.
Thiazolidinediones
Thiazolidinediones (e.g. pioglitazone) are peroxisome pro-
liferator-activated receptor γ modulators, and thus increase 
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the sensitivity of muscle, fat and liver to endogenous 
insulin (“insulin sensitisers”). Caution should be advised 
when initiating this group of drugs, as they carry an 
increased risk of fluid retention, congestive heart failure 
and fractures in women.18,19 SEMDSA recommends the 
use of thiazolidinediones in a selected group of patients, 
such as obese individuals who cannot tolerate metformin. 
They reduce HbA1c by 0.5 to 1.4%. There are no long-term 
outcome studies on these agents as yet.
Incretin-based therapies 
These are newer therapies available in South Africa. The 
two most recently approved classes of therapeutic agents 
for the treatment of type 2 diabetes mellitus are glucagon-
like peptide-1(GLP-1) receptor agonists and dipeptidyl 
peptidase-4 (DPP4) inhibitors. They exert their action 
through potentiation of incretin receptor signalling. Incretin 
hormones are released from the small intestine at mealtimes 
and increase glucose-dependent insulin secretion from the 
pancreas. GLP-1 also suppresses glucagon production and 
works on the brain, promoting a feeling of satiety as well as 
regulating gastric emptying. 
This group of drugs provides a new option for the treatment 
of type 2 diabetes mellitus and enables intensification of 
therapy whilst controlling body weight and lowering the risk 
of hypoglycaemia.20 The most common adverse effect is 
nausea, which wanes over time. In addition, association with 
pancreatitis has been suggested but remains contentious. 
A major benefit of GLP-1 analogues is weight loss. The 
incretin-based therapies are less well-validated therapies 
and there are no long-term outcome studies as yet.
Insulin
Insulin may be considered a first-line therapy or second- 
or third-line therapy as add-on to oral agents. SEMDSA 
recommends insulin as first-line therapy in the case of 
severely uncontrolled diabetes with catabolism. This 
includes patients with fasting plasma glucose of  greater 
than 14 mmol/l, random glucose levels consistently in 
excess of 16.7 mmol/l, HbA1c over 10%, or the presence of 
ketonuria, or in a patient who is symptomatic with polyuria, 
polydipsia, and significant weight loss. 
Once-daily basal insulin may be an appropriate transition. 
Analogue basal insulin may be considered in patients with 
hypoglycaemia. Because of their pharmacokinetic profile, 
analogues have the advantage of lessening the risk of 
hypoglycaemia and thus allowing patients to achieve their 
glycaemic targets at lower risk of developing hypoglycaemia. 
Biphasic insulin would be the next appropriate step, during 
which time metformin should be continued. Multiple daily 
injections should be considered if the above does not result 
in glycaemic targets being met; however, it is important to 
realise that this regimen may be the method of choice at the 
outset in selected patients. 
SEMDSA recommends the following insulin implementation: 
Basal insulin should be started with 10 units of intermediate-
acting (NPH) or long-acting insulin at bed time. This should 
be increased by two units every three to seven days until 
the fasting glucose target is met. SEMDSA recommends a 
preprandial target of 4-7 mmol/l. One should continue with 
metformin and possibly sulphonylurea when adding basal 
insulin. Biphasic insulin should be started with a total dose 
of 0.4 U/kg, with two-thirds initially administered before 
breakfast and one-third before supper. The morning dose is 
titrated according to pre-supper readings and the evening 
dose according to pre-breakfast readings. If the glycaemic 
targets are not met, intensive insulin therapy with multiple 
daily injections should be considered. Specialist referral 
should be considered at any stage, especially if glycaemic 
targets are not met, as the above guidelines may have to 
be individualised to ensure safe insulin implementation. The 
role of a diabetes educator as well as a registered dietitian 
cannot be emphasised enough, especially once the patient 
is on insulin therapy. Injection technique, safe handling 
of medical waste and in-depth knowledge of the insulin 
regimen, as well as insulin type and mode of action, are 
crucial to safe and effective implementation. 
Cardiovascular risk management
The Steno-2 study emphasises the importance of intensified 
multifactorial intervention.21
Blood pressure control
Diagnosis of hypertension is made if the BP is found to be 
≥ 130 mmHg systolic and ≥ 80 mmHg diastolic on two 
separate days.2,4 A goal of systolic BP < 130 mmHg and 
diastolic BP < 80 mmHg is appropriate for most patients. A 
recently published article suggests that reducing systolic BP 
to < 130 mmHg among patients with diabetes and coronary 
artery disease (CAD) is not associated with further reduction 
in morbidity beyond that associated with systolic BP 
< 140 mmHg. The findings of this study indeed suggest that 
such lowering of systolic BP is in fact associated with an 
increase in risk of all-cause mortality.22 The ADA suggests 
that, pending further analyses and results, previously 
suggested targets are appropriate. 
Angiotensin-converting enzyme (ACE) inhibitors or angio-
tensin-receptor blockers (ARBs) should be considered as 
first-line therapies, while monitoring of serum potassium 
and creatinine is recommended. SEMDSA recommends 
that low-dose thiazide or loop diuretics (if the estimated 
glomerular filtration rate is ≤ 50 ml/minute) should be added 
if BP target is not achieved. SEMDSA also recommends 
that a combination of an ACE inhibitor and ARB should be 
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avoided, as well as the combination of either of the two 
with spironolactone, as potassium may rise to dangerous 
levels. If BP is refractory to optimal doses of at least three 
antihypertensive agents of different classes, the clinician 
should consider evaluation for a secondary causes of 
hypertension. 
Dyslipidaemia management
A fasting lipid profile should be obtained at least annually. 
SEMDSA recommends statin therapy as the first-line agent 
for lowering low-density lipoprotein (LDL) cholesterol in 
diabetic patients. Statin therapy should be added to lifestyle 
interventions, irrespective of baseline lipid profile, for all 
patients with existing CAD and those older than 40 years 
of age who have one or more additional cardiovascular risk 
factors. For patients at lower risk, statin therapy should be 
considered if the LDL cholesterol remains above 2.5 mmol/l, 
despite adequate lifestyle modification and glycaemic 
control. 
SEMDSA recommends the following targets: LDL cholesterol 
< 2.5 mmol/l, HDL cholesterol > 1.0 mmol/l in men and 
> 1.2 mmol/l in women, and triglycerides < 1.7 mmol/l.4 The 
ADA recommends the following targets: LDL cholesterol 
< 2.6 mmol/L in those without overt cardiovascular disease 
(CVD), < 1.8 mmol/l in those with CVD, HDL cholesterol of 
> than 1.0 mmol/l in men and > 1.3 mmol/l in women, and 
triglycerides < 1.7 mmol/l.2 The primary objective with the 
majority of the patients with diabetes is to lower the LDL 
cholesterol, an exception being patients presenting with 
severe hypertriglyceridaemia.23
Lifestyle intervention, including nutritional intervention, 
weight loss, increased physical activity and smoking 
cessation, should also be emphasised. Two trials were 
specifically designed to investigate lipid management 
in patients with diabetes. In the Atorvastatin Study for 
Prevention of Coronary Heart Disease Endpoints in Non-
Insulin-Dependent Diabetes Mellitus (ASPEN), the primary 
end-point did not reach statistical significance but the 
point estimate for CVD benefit observed in the secondary 
prevention cohort for fatal and nonfatal myocardial infarction 
supported the rationale for statin therapy in patients with 
diabetes.24 Primary prevention of CVD with atorvastatin in 
type 2 diabetes mellitus in the Collaborative Atorvastatin 
Diabetes Study (CARDS) posed the interesting question 
of whether any patient with type 2 diabetes mellitus is at 
sufficiently low risk for statin therapy to be withheld.25 
Antiplatelet agents
In January 2011, the ADA issued recommendations regarding 
antiplatelet therapy in patients with type 2 diabetes mellitus. 
One should consider aspirin therapy as a primary prevention 
strategy in those with type 2 diabetes mellitus at increased 
cardiovascular risk (10-year risk > 10%). This includes most 
men over 50 years of age or women over 60 years of age 
who have at least one additional major risk factor (family 
history of CVD, hypertension, smoking, dyslipidaemia 
or albuminuria). Aspirin should not be recommended for 
CVD prevention for adults with diabetes at low CVD risk 
(10-year risk < 5%, such as in men under 50 years of age 
and women under 60 years of age with no major additional 
CVD risk factors), since the potential adverse effects from 
bleeding probably offset the potential benefits. In patients 
in these age groups with multiple other risk factors, clinical 
judgement is required. 
Aspirin therapy should be used for secondary prevention 
in those with diabetes and history of CVD. The use of 
aspirin as primary prevention in patients with diabetes at 
increased CV risk, including those over 40 years or those 
with additional risk factors, was previously recommended 
by the ADA and the American Heart Association (AHA). 
However, the net benefit of aspirin in primary prevention is 
controversial and, based on more recent evidence in 2010, 
a position statement has been issued by the ADA, AHA, and 
the American College of Cardiology Foundation, updating 
the prior recommendations for primary prevention.26
Smoking cessation
It is recommended to advise all patients not to smoke.
Treatment goals
The treatment goals recommended by SEMDSA for patients 
with type 2 diabetes mellitus are summarised in Table I, and 
those recommended by the ADA in Table II.
Table I: The proposed targets of SEMDSA for most adults with type 2 
diabetes mellitus (2009)
Glycated haemoglobin HbA1c (%) < 7
Body mass index BMI (kg/m2) < 25
Blood pressure Systolic mmHg < 130 
Diastolic mmHg < 80 
Total cholesterol mmol/l < 4.5
aLDL cholesterol mmol/l < 2.5 
bHDL cholesterol mmol/l
> 1.0 (men),  
> 1.2 (women)
Triglycerides mmol/l < 1.7
Table II: The proposed targets of the ADA for most adults with type 2 
diabetes mellitus (2011)
Glycated haemoglobin HbA1c (%) < 7
Blood pressure mmHg < 130/80
aLDL cholesterol mmol/l < 2.6
a = low-density lipoprotein
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Screening for complications
Cardiovascular disease
In asymptomatic patients, routine screening for CAD is not 
recommended. All CVD risk factors should be treated and 
assessed at least annually. A full discussion of the screening 
for CVD is beyond the scope of this review and was updated 
in a recent consensus statement.27
Nephropathy
Annual tests to assess urine albumin excretion are 
recommended. Serum creatinine should be measured 
at least annually and should be used to calculate the 
glomerular filtration rate (GFR) and stage the level of chronic 
kidney disease. The rationale for this stems from the well-
documented observation that GFR may decline in a patient 
with type 2 diabetes mellitus without a concurrent increase in 
albumin excretion. Microalbuminuria is defined as excretion 
of 30 to 299 mg of albumin per day in a random urine 
specimen. This progresses to macroalbuminuria, defined 
as excretion of 300 mg or more per day of albumin or an 
albumin:creatinine ratio over the above-mentioned limits, or 
higher in a random urine specimen. In patients with type 2 
diabetes mellitus, hypertension and microalbuminuria, ACE 
inhibitors and ARBs have been shown to delay progression 
to macroalbuminuria.28 In patients with type 2 diabetes 
mellitus, hypertension, macroalbuminuria and renal 
insufficiency, ARBs have been shown to delay progression 
to nephropathy.29 It is important to also emphasise the 
importance of monitoring serum potassium when using 
ACE inhibitors or ARBs.
Retinopathy
All patients with type 2 diabetes mellitus should have an 
initial dilated and comprehensive eye examination by an 
ophthalmologist shortly after the diagnosis of diabetes, 
as eye complications may be evident at diagnosis. This 
is because type 2 diabetes mellitus often has a long 
asymptomatic phase and there may be a gap of many 
years between onset and diagnosis. Cataracts also need 
to be identified and managed accordingly. Subsequent 
examination should be performed annually or more 
frequently if retinopathy is progressing. 
Neuropathy
Similarly, all patients with type 2 diabetes mellitus should be 
screened for distal symmetric polyneuropathy at diagnosis 
and at least annually, using simple diagnostic tests such 
as pin-prick sensation, vibration perception using a 128 Hz 
tuning fork and 10 g monofilament, and ankle reflexes. 
Similarly, screening for signs and symptoms of autonomic 
neuropathy should be instituted at diagnosis. Pointers 
include resting tachycardia, exercise intolerance, ortho-
static hypotension, constipation, gastroparesis, erectile 
dys-function, sudomotor dysfunction and autonomic failure 
in response to hypoglycaemia.
Foot care
Annual comprehensive foot examination is recommended 
for all patients with type 2 diabetes mellitus. The foot 
examination should include inspection for any abnormalities, 
assessment of foot pulses, 10  g monofilament testing, 
vibration perception, pinprick sensation and ankle reflexes. 
It is important to provide education in foot self-care. A 
comprehensive foot examination and risk assessment 
report was published in 2008.30 
Education and team approach
It is widely accepted that successful care of a patient 
with type 2 diabetes mellitus relies on a team approach. 
Type 2 diabetes mellitus is a chronic disease and lifetime 
support by a multidisciplinary team, as well as education 
in self-care, is vital. The team should consist of a certified 
diabetes educator, a registered dietitian, a registered nurse 
and a primary care physician with specialist support. Other 
team members, such as cardiologists, nephrologists, 
ophthalmologists, psychologists and podiatrists, may be 
warranted.5 Patient education is a cornerstone of effective 
diabetes care, as emphasised by SEMDSA.  
Patient self-management is the key to success and 
education should be provided by appropriately trained 
educators and registered dietitians. Small-group education 
is an option if this is acceptable to the patient (remember 
confidentiality). Basic knowledge of diabetes, importance 
of good and comprehensive control, lifestyle interventions, 
use of medications, recognition and management of acute 
and chronic complications, foot care, pregnancy, smoking 
and alcohol, and psychosocial issues, should all be covered 
during the education.
Summary and conclusion
Diabetes causes approximately 5% of deaths globally 
each year. Eighty per cent of patients with diabetes live in 
low-income and middle-income countries. What is most 
disturbing is the World Health Organization (WHO) prediction 
that without urgent action, diabetes deaths will increase by 
more than 50% in the next 10 years.31 World Diabetes Day 
raises the global awareness of diabetes, thus providing 
an additional opportunity to educate patients, healthcare 
professionals, carers, spouses and family, as well as the 
public in general. This day, initiated by the International 
Diabetes Federation and the WHO, and celebrated on 
14 November, marks the birthday of Frederick Banting, 
who, together with Charles Best, played a crucial role in 
discovery of insulin in 1922.32
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Returning to the case scenario, this patient clearly has 
type 2 diabetes mellitus with major risk factors for CVD. 
Therapy should be initiated with lifestyle interventions, 
including a weight-reducing diabetic diet and a graduated 
exercise programme. Metformin should be first-line therapy. 
If glycaemic targets are not met, a sulphonylurea-type 
drug should be added. Basal insulin therapy is indicated 
if this combination of oral hypoglycaemic agents fails to 
achieve glycaemic targets. The patient should be made 
aware of new therapies such as incretins, which are now 
available. The patient’s cardiovascular risk factors need to 
be addressed. His BP must be reduced to target, starting 
with an ACE inhibitor (or ARB if intolerant). Most often 
multiple drug therapy is required to reduce the BP to target. 
The dyslipidaemia needs to be addressed with lifestyle 
interventions and statin therapy. He meets the criteria for low-
dose aspirin therapy. Screening for complications should 
be implemented at diagnosis, especially as this patient 
presented with visual symptoms and microalbuminuria. 
Comprehensive diabetes education is crucial to ensure 
successful management of this patient.
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